Ontology highlight
ABSTRACT:
SUBMITTER: Kuemmel S
PROVIDER: S-EPMC7382468 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
NPJ breast cancer 20200724
There is a strong biologic rationale that poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors may benefit a broader range of metastatic breast cancer (MBC) patients than covered by current approvals, which require a germline <i>BRCA1/2</i> sequence variant affecting function. We report a patient with germline/somatic <i>BRCA1/2</i> wild-type MBC, who had a dramatic response to the PARP inhibitor olaparib of at least 8 months' duration. The patient is a 37-year-old woman with recurren ...[more]